Clinical Trial Update: Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. [Phase 1]

View source ↗

Summary

A completed Phase 1 trial evaluating the safety and preliminary efficacy of Fate Therapeutics' ProHema modulated umbilical cord blood units in patients with hem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• ProHema Modulated Umbilical Cord Blood Units

Snippet

Sponsor: Fate Therapeutics | Conditions: Hematologic Malignancies, Allogeneic Stem Cell Transplantation | Phase 1 | Status: COMPLETED